Close
Help





JOURNAL

Clinical Medicine Reviews in Therapeutics

Does Belimumab Reduce Disease Activity in Adults with Systemic Lupus Erythematosus?

Submit a Paper


Clinical Medicine Reviews in Therapeutics 2012:4 71-78

Opinion

Published on 02 Feb 2012

DOI: 10.4137/CMRT.S6575


Further metadata provided in PDF

Download Article PDF


Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics

Abstract

In March 2011, the FDA approved belimumab (Benlysta) for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. Belimumab is a fully human monoclonal antibody directed against BLyS (B lymphocyte stimulator). BLyS, a member of the TNF ligand super family, promotes the survival and maturation of B cells. For patients on standard of care therapy and without active severe renal or central nervous system lupus, belimumab has been shown to be effective and safe. Further information will be gathered in the open label extensions of the phase II and III trials and post-marketing experience.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services